This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

28 Jan 2011

Cetero Research Announces Completion of 20,000th Early-Phase Clinical Study

Cetero's position as the leader in early-phase clinical development is solidified with the completion of 20,000 studies.

Cetero Research, the leading early-stage contract research organization (CRO), announced that it has reached another industry milestone with the completion of its 20,000th early-phase clinical trials.


The achievement solidifies Cetero's position as the unmatched leader in early-phase clinical development and highlights the range of study experience and therapeutic expertise that Cetero offers to pharmaceutical, biotechnology and generic clients.


"We are very proud of this extraordinary accomplishment, which has been made possible by our dedicated staff and loyal clients," said Troy W. McCall, PhD, Chief Executive Officer of Cetero. "One of the best measures of a CRO's capabilities is its depth and breadth of experience. Cetero can offer clients more efficient cli

Related News